NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

seekazy,

It sounds like you’re spreading rumors 😶

It’s highly misleading to characterize CHM’s review as negative. The committee’s advice to the MHRA about DCVax-L has not been published.



Review the CHM annual reports published by MHRA. There are many new pharma products that CHM advised MHRA about before they were granted full or conditional approvals…

For example, CHM advised MHRA on the MAA for Casgevy before its approval made headline news around the world…

Consider the Oct 2023 CHM minutes referencing Casgevy during the month before MHRA’s approval
announcement was published in Nov 2023…




MHRA Approves Casgevy


Imperial College London


Worldwide Clinical Trials



In CHM’s own annual report, they highlighted their advisory role in the review of Casgevy, along with other noteworthy approvals…
“CHM continued to carefully consider the data on quality, efficacy & safety of a number of new active substances and after detailed deliberations on diverse issues, advised the MHRA on the approvability of …

• Casgevy (exagamglogene autotemcel), a gene therapy product based on innovative gene-editing CRISPR tool for treatment of sickle-cell disease and
transfusion dependent ß-thalassemia, which was approved first in the UK before any other country in the world.”

CHM 2023 Annual Report

CHM 2024 Annual Report

Dr. Shirley Hopper, MHRA